Scarica l'app Stockscreener
1.315
5.76%
-0.075
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.39
Aprire:
$1.34
Volume 24 ore:
2.18M
Relative Volume:
0.54
Capitalizzazione di mercato:
$252.93M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-0.6203
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
-18.63%
1M Prestazione:
-17.09%
6M Prestazione:
-33.16%
1 anno Prestazione:
-58.01%
Intervallo 1D:
$1.28
$1.35
Intervallo di 1 settimana:
$1.28
$1.62
Portata 52W:
$1.28
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.3158 | 252.93M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
161.25 | 73.88B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 48.17B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.59B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.07 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.90 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion Appoints Robert E. Hoffman as New Director - TipRanks
Esperion Appoints Robert E. Hoffman to Board of Directors - GlobeNewswire
Strategic Board Shake-up: Esperion Lands Former Kintara CEO Hoffman as Director - Stock Titan
Esperion stock hits 52-week low at $1.46 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $1.46 amid challenges - Investing.com India
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive: Esperion Reveals Next-Gen Drug Pipeline at Major Healthcare Conference - Stock Titan
BB Biotech AG Reduces Stake in Esperion Therapeutics Inc - GuruFocus
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia - Nasdaq
Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia - MarketScreener
Esperion Aligns with U.S. Food and Drug Administration to - GlobeNewswire
Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid - StreetInsider.com
FDA Backs Esperion's Breakthrough Move into Pediatric Cholesterol Treatment - Stock Titan
Esperion Therapeutics chief commercial officer sells $3,617 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CFO sells $5,242 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CEO Koenig sells $19,622 in stock By Investing.com - Investing.com South Africa
Esperion Therapeutics CEO Koenig sells $19,622 in stock - Investing.com
Esperion Therapeutics CFO sells $5,242 in stock - Investing.com India
Esperion Therapeutics chief commercial officer sells $3,617 in stock - Investing.com
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN
Esperion stock hits 52-week low at $1.55 amid market challenges - Investing.com Australia
Esperion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa
Q3 Earnings Forecast for ESPR Issued By HC Wainwright - Defense World
Esperion Therapeutics, Inc. SEC 10-K Report - TradingView
Esperion Therapeutics Inc. (ESPR) reports earnings - Quartz
Brokers Set Expectations for ESPR Q1 Earnings - Defense World
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Analysts - Defense World
Esperion stock target holds at $4 on JMP’s optimistic outlook By Investing.com - Investing.com South Africa
Esperion stock target holds at $4 on JMP’s optimistic outlook - Investing.com
Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright - Defense World
Esperion Therapeutics: Q4 Earnings Snapshot - Barchart
Esperion stock hits 52-week low at $1.58 amid challenges By Investing.com - Investing.com Australia
Esperion Therapeutics Reports Strong Revenue Growth in 2024 - TipRanks
Esperion Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Esperion Therapeutics stock surges over 9% on strong Q4 results - Investing.com
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Esperion Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Esperion Therapeutics Q4 Loss Narrows - Nasdaq
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Esperion Therapeutics stock surges over 9% on strong Q4 results By Investing.com - Investing.com Canada
ESPERION THERAPEUTICS Earnings Results: $ESPR Reports Quarterly Earnings - Nasdaq
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
7.85%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):